The Big Interview: Novartis CTO Elizabeth Theophille

“One of our major focuses for the future four-six many years will be to refresh our SAP landscape which will require a total overhaul…”

Pharmaceuticals’ instant in the sunshine arguably arrived with COVID-19, when an business usually demonised as “Big Pharma” commenced attracting broader recognition as a truly revolutionary one that is central to preventing to the pandemic and one which will be at the coronary heart of responding to any other upcoming community health crises.

Pharma has drawn clean attention from those doing the job in the tech sector as a result. The plan of marrying an mental challenge with a social good — reverse engineering a personal computer virus, and undertaking the very same to a real virus to uncover ways in which to restore a procedure to health is amid the evident parallels — appears to have struck a chord throughout the tech globe a little something born out by current surveys. (The actuality that it is a hugely profitable business capable to remunerate expertise effectively may perhaps also support.)

That shift in community sentiment was tidily captured in a study of 2,five hundred technology specialists — in China, Germany, India, the British isles, and the US — by Switzerland’s Novartis, done in May possibly and June 2020: this uncovered that 72% of tech specialists are more likely to think about pharma for their future task in comparison to six months back. (The study also recommended that healthcare and prescription drugs were being now more than 2 times as interesting as monetary solutions, telecoms and producing to tech expertise.)

Novartis CTO: “We’re all fishing in the very same pond”

They’re wanted: throughout the sector, big operate is underway to innovate: as Bertrand Bodson, CDO of Novartis, places it: “COVID-19 has induced a seismic shift in the adoption and scaling of digital systems in our sector, at a speed never ever viewed just before.”

Novartis’ Elizabeth Theophille, Head of Technological innovation, Architecture and Electronic (a de facto CTO role) is amid those who built the shift from other sectors. Formerly Group CIO at Nokia, she admits she knew minimal about pharma when she joined the business: “I was almost certainly some of the first tranches when Novartis were being wanting for tech specialists that never ever had a healthcare background”, she explained to Laptop or computer Business Evaluate in a phone.

“We’re currently being more open up to uncover expertise from other industries, because we’re all fishing in the very same pond when it will come to acquiring good people today: engineers, facts researchers people today that can establish and architect cloud methods and support business transformation.”

Speaking from Paris, she painted a photo of a varied crew at the business, doing the job on many overlapping facts science, automation and cloud engineering worries: “I have a crew of about 300 associates. I have a huge crew of architects I have a crew of facts researchers I have a crew of automation specialists: a myriad of expertise throughout my business – and they arrive from diverse backgrounds as effectively.”

Cloud-run innovation 

It is a major transition for an business very long-viewed as deeply conservative and risk averse. Component of that shift has arrive with an expanding openness to the cloud, which has aided break down inside siloes and decrease technical debt, she suggests.

As CTO, Theophille notes: “I am also leading the architecture, style and establish of the ‘Novartis Company Information and Analytics Platform’ which is a multi-cloud platform run by AWS & Azure.  This platform will keep our wide quantities of facts throughout Novartis that the business will use for new insights and decisions…”)

“I believe a major transformation has been about employing cloud Platform-as-a-Support (PaaS) to establish new methods we could definitely begin to get far better insights and decisions from the facts that we place on the cloud, no matter if that was industrial facts, advertising and marketing facts, clinical trials and so on. We’ve also been constructing a whole lot more client encounter programs on the cloud. There has been a major alter in state of mind [at Novartis] about sharing facts at an organization level, in its place of retaining that on your have committed server. There’s a whole lot more believe in in in how we collaborate as an organisation.”

New (as of 2018) Novartis CEO Vasant Narasimhan has been vocal on this, and the need to make better use of facts. The company’s 2019 yearly report [pdf] captured some of his thinking, together with the actuality that the business has now gathered somewhere around two million individual many years of facts by clinical trials alone.

As Narasimhan pointed out: “We’re having techniques to make the most of this strategic asset. In 2019, we expanded and launched major facts and digital initiatives when forming new collaborations to increase our expanding inside abilities.”

He additional: “We’re integrating substantial quantities of facts that beforehand existed in silos within and exterior the business and having a holistic look at it. The facts ranges from pictures of cells that have been dealt with with diverse chemicals, to blood samples from people analyzed inside clinical trials. We’re employing device studying and synthetic intelligence to mine the integrated, anonymized facts for connections and styles that are indiscernible to the human brain. Our facts researchers are constructing models and programs that will empower Novartis teams to inquire new queries, make far better predictions and preserve time. We can use the platform to prioritize drug targets, recognize improvement alternatives for compounds, and more.

Novartis CTO: Offer chain planning is a expanding portion of the role

“To make acquiring of program materials more successful, we are standardizing specifications and consolidating suppliers. The case in point of laboratory gloves illustrates our development: We went from a hundred diverse sorts of laboratory gloves all over the world to just fourteen, and from 55 suppliers to one, conserving USD .six million. We are also constructing a databases to present a more detailed check out of our buying and are starting up to use facts analytics to support us far better deal with what we invest in, when and from whom.”

That is a major concentrate for CTO Elizabeth Theophille, who explained to us: “I have a major concentrate proper now on how we do desire planning for provide chain how we look at our interactions with HCPs (healthcare specialists) and the encounter that they get, specially when they be a part of Novartis occasions. I also look at how we simplify the way we deal with articles from a digital asset administration viewpoint and how we approve all of our materials that commercially get extended to HCPs. And I’m just wanting at how we can use technology and business approach to to alter the way we operate.”

“We have robots alive and kicking”

This involves overhauling the finance function: “We have commenced to establish robots employing Microsoft Azure: employing this to essentially provide alongside one another software package automation and to simplify many of the sophisticated procedures that we have at Novartis.

“We have robots stay alive and kicking at Novartis – most of them are undertaking a whole lot of automation in our monetary solutions location. We’ve also automated the pharmacovigilance procedures where by, you know, we have to report adverse events”

What’s the major pending project then?

“Every yr we overview our Technological innovation Outlooks dependent on the business method and new rising tech. In my role I have Technological innovation Refresh and consider new rising technology.  One particular of our major focuses for the future 4 – six many years will be to refresh our SAP landscape which will require a total overhaul in business approach transformation, technology upgrades and new ways of working…”

(CTOs and CIOs globally will recognise the complications that can arrive with this — and the temptation to go away it to past in huge digital transformation checklist).

“This is an astounding time for the digital transformation of health care”, she concludes. “It’s genuinely been a impressive journey above the earlier handful of many years. We’ve invested a important volume of funds, and [forged] partnerships with Microsoft, AWS and other organisations to support us change employing their cloud technology to analyse our facts and provide our facts alongside one another and to establish facts science and AI models.

“The pharmaceutical business is unquestionably necessary to support people. So it’s it’s definitely essential that we get a diversity of awareness and encounter from other industries that can support us speed up this digital transformation.”

See also: The Huge Interview – Former GCHQ Director Robert Hannigan